Hepatocellular carcinoma (HCC) is the most frequent primary malignant liver tumor, with
more than 800,000 new cases diagnosed each year and with high mortality, ranking fourth …

Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related deaths and
the fifth most common cancer worldwide. Most of these patients are seen with advanced …

Hepatocellular carcinoma (HCC) is a significant cause of mortality in patients with chronic
liver disease around the world. Development of biomarkers for early HCC detection is a …

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths
worldwide. If diagnosed early, curative treatment options such as surgical resection, loco …

Hepatocellular carcinoma (HCC), one of the leading causes of cancer deaths in the world, is
offering a challenge to human beings, with the current modes of treatment being a palliative …

Despite of the advances in clinical imaging and applied research in proteomic biomarkers,
liver cancer, especially hepatocellular carcinoma remains detected at the very late and …

Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide. The
HCC diagnosis is usually achieved by biomarkers, which can also help in prognosis …

New biomarkers of hepatocellular carcinoma (HCC) have been identified using advanced
genomic, proteomic, and metabolomics technologies. These are being developed not only …

Hepatocellular carcinoma (HCC) stands third among cancer-related deaths globally. Owing
to its high incidence and linked mortality, early diagnosis is alarming for patient survival and …

The past decades have witnessed increased use of biomarkers in disease management. A
biomarker is any characteristic that can be objectively measured and evaluated as an …